CD165, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD165, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD165, Human |
| Clone | REA1199 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 |
| Format | biotin conjugate |
| Size | 30 tests in 60 µL |
| Concentration | 1:50 |
| Applications | Flow cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD165 Antibody, anti-human, Biotin, REAfinity™. Clone REA1199 recognizes the human CD165 antigen, also known as AD2, which is 37-42 kDa cell surface glycoprotein expressed on most thymocytes, thymic epithelial cells, most platelets, fibroblasts, acute T-lymphoblastic leukemia cells (T-ALL cells), central nervous system neurons, islet cells of the pancreas, and Bowman?s capsule of the kidney. CD165, which is similar to TALLA-1 (CD231, T-cell acute lymphoblastic leukemia antigen), plays a role in cell adhesion between thymocytes and thymic epithelial cells during development. | Additional information: Clone REA1199 displays negligible binding to Fc receptors. |
| Immunogen | n/a |
| Other Names | AD2, gp37 |
| Gene, Accession # | n/a |
| Catalog # | 130-122-830 |
| Price | $94 |
| Order / More Info | CD165, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Seon, B. K. (1995) Similarity of TALLA-1, a T-cell acute lymphoblastic leukemia antigen, to GP37. Int. J. Cancer 63 (3): 474. | Takagi, S. et al. (1995) Identification of a highly specific surface marker of T-cell acute lymphoblastic leukemia and neuroblastoma as a new member of the transmembrane 4 superfamily. Int. J. Cancer 61 (5): 706-715. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies